BioWorld

July 18, 2006

Threshold Dives On Lack Of Efficacy In BPH Trials

Shares of Threshold Pharmaceuticals Inc. lost more than half their value after the company said it was dropping its benign prostatic hyperplasia drug, TH-070, following misses in Phase II and Phase III studies. (BioWorld Today) Read More

Actelion, Roche Sign $630M Autoimmunity Product Deal

Senate Scheduled To Take Vote Today On Pivotal ESC

Tigris Licenses Aminoflavone Prodrug For Cancer From NIH

Concert Pharma Brings In $10M Via Series A Round

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Flow Neuro wins FDA nod for at-home device for depression

BioWorld MedTech

Flow Neuroscience AB received U.S. FDA 510(k) approval for its Flow at-home brain-stimulation device to treat major depressive disorder. The wearable headset uses...